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To  the  Editor,
The  introduction  in  clinical  practice  of  the  new
direct-acting  antiviral  agents  (DAAs)  has  induced  dramatic
advances  in  the  management  of  chronic  HCV  infection  [1].
Recent  reports  demonstrated  that  DAAs  were  associated
with  a  rapid  improvement  of  fasting  glucose  (FG)  and  gly-
cated  haemoglobin  (HbA1c)  values  in  diabetic  HCV-infected
patients  during  treatment  [2].  The  underlying  mechanism
of  these  clinical  observations  has  not  yet  been  elucidated.
Here,  the  circulating  levels  of  proteins  related  to  IR  such  as
adiponectin  (ADPN),  selenoprotein  P  (SelP),  fetuin  A  (FetA),
and  the  cytokine  interleukin-6  (IL-6)  were  assessed  in  HCV-
infected  patients  receiving  an  interferon-free  regimen.
The  study  population  included  31  patients  with  active
HCV  infection,  16  were  HIV/HCV  co-infected  and  15  were
HCV  mono-infected.  Among  this  population,  we  were  able
to  identify  14  diabetic  and  17  non-diabetic  patients.  The
median  age  of  diabetic  and  non-diabetic  patients  was  61
and  54  years,  respectively.  Most  patients  were  male  (79%  of
diabetics,  59%  of  non-diabetics).  The  most  frequent  geno-
type  was  genotype  1.  Many  patients  had  severe  or  advanced
fibrosis  (100%  of  diabetics,  71%  of  non-diabetics).  All  HIV
positive  patients  had  undetectable  HIV-RNA  (<  50  copies/mL)
and  all  but  one  (elite  controller)  were  treated  with  differentPlease  cite  this  article  in  press  as:  Pavone  P,  et  al.  Systemic  adipo
and  HCV/HIV  coinfected  patients  treated  with  direct  antivira
https://doi.org/10.1016/j.clinre.2018.02.004
antiretroviral  regimens.  Among  the  diabetic  patients,  three
were  receiving  metformin,  six  were  receiving  insulin,  one
repaglinide  and  four  patients  were  not  receiving  treatment
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2210-7401/© 2018 Published by Elsevier Masson SAS.or  T2DM.  The  patients  were  treated  with  interferon-free
AAs  according  to  the  European  Guidelines  for  HCV  treat-
ent  at  the  time  of  enrolment  (year  2015).  In  diabetic
atients,  we  assessed  FG  and  HbA1c  values  at  baseline  and
t  the  end  of  treatment  (EOT).
Blood  samples  were  collected  from  each  patient  at  base-
ine  and  at  the  EOT.  Commercially  available  ELISA  were
sed  for  the  quantitative  detection  of  plasma  levels  of  SelP
Elabscience  Biotechnology  Co.,  USA),  ADPN,  FetA  and  IL-6
Quantikine,  R&D  Systems,  Minneapolis,  MN),  according  to
he  manufacturer’s  instructions.  A  statistical  analysis  was
erformed  using  Prism  Software  7.  We  used  Wilcoxon  test
or  paired  samples,  Mann—Withney  test  for  non-paired  sam-
les.  We  also  performed  Pearson’s  correlation  coefficient
or  parametric  analyses  and  Spearman’s  correlation  coef-
cient  for  non-parametric  analyses.  Results  were  expressed
s  median  values  and  interquartile  range  (IQR).  The  study
as  approved  by  the  local  institutional  review  board.  All
tudy  participants  signed  an  informed  written  consent  at  the
ime  of  inclusion.
At  the  EOT,  all  patients  had  undetectable  HCV-RNA  and
LT  values  within  the  normal  range.  Baseline  FG  median
alue  (MV)  was  139  mg/dell  (IQR  =  86  mg/dL),  EOT  FG  median
alue  was  118  mg/dL  (IQR  =  52  mg/dL).  Baseline  HbA1c  MV
as  6.90%  (IQR  =  1%),  EOT  HbA1c  MV  was  6.80%  (IQR  =  2.35%).
t  the  EOT,  FG  MV  was  reduced  (P  =  0.006),  whereas  a  non-
ignificant  reduction  of  HbA1c  was  observed.
The  levels  of  biomarkers  before  and  at  the  end  of  treat-
ent  are  reported  in  Fig.  1. The  ADPN  MV  at  baseline  in  the
1  HCV-infected  patients  was  6.11  g/mL,  IQR  =  6.76  g/mL
nd  a  significant  reduction  (P  =  0.005)  was  observed  at  the
OT  (4.85  g/mL,  IQR  =  4.52  g/mL).  Likewise,  for  ADPN,
elP  plasma  levels  were  also  significantly  reduced  at  the
OT  (baseline  MV  =  20.18  g/mL,  IQR  =  47.01  g/mL;  EOT
V  =  11.43  g/mL,  IQR  =  9.39  g/mL;  P  =  0.0011).  We  did  not
bserve  any  significant  variation  of  FetA  and  IL-6  plasma
evels  during  DAA  treatment  in  the  study  population.
The  levels  of  biomarkers  according  to  the  presence
f  diabetes  and  HIV  coinfected  are  displayed  in  Table  1.
 statistical  significant  reduction  of  FetA  was  observedkines,  hepatokines  and  interleukin-6  in  HCV-monoinfected
l  agents  (DAAs).  Clin  Res  Hepatol  Gastroenterol  (2018),
n  HIV-negative  patients  (baseline  MV  =  2.49  mg/mL,
QR  =  1.87  mg/mL,  EOT  MV  =  1.06  mg/mL,  IQR  = 1.05  mg/mL,
 =  0.02),  whereas  no  significant  variations  were  found  in
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Higure  1  Circulating  levels  of  ADPN,  SelP,  FetA  and  IL-6  in  31
ere measured  at  baseline  and  end  of  treatment  (EOT)  with  DA
IV/HCV  coinfected  patients.  IL-6  median  values  were
ignificantly  higher  in  co-infected  than  in  mono-infected
atients,  at  baseline  (MV  HIV-positive  =  5.02  pg/mL,  MV
IV-negative  =  1.78  pg/mL,  P  =  0.0071)  and  at  EOT  (MV
IV-positive  =  4.74  pg/mL,  MV  HIV-negative  =  2.29  pg/mL,
 =  0.015).
ADPN  levels  were  significantly  higher  in  women  than
en,  both  at  baseline  (MV  in  women  =  12.52  g/mL,  MV
n  men  =  5.39  g/mL,  P  =  0.035)  and  at  the  EOT  (MV  in
omen  =  10.55  g/mL,  MV  in  men  3.72  g/mL,  P  =  0.025).
e  also  noted  that  the  reduction  of  SelP  was  greater
n  women  (baseline  MV  =  23.69  g/mL,  IQR  =  23.19  g/mL,
OT  MV  = 11.43  g/mL,  IQR  =  8.83  g/mL;  P  =  0.0195)  than  in
en.  Finally,  we  found  that  baseline  ADPN  values  were  posi-
ively  correlated  with  ALT  levels  (Spearman  correlation  test,
 =  0.60,  P  =  0.0008)  and  HbA1c  values  (Spearman  correlation
est,    =  0.75,  P  =  0.066).
In  the  present  study,  we  demonstrated  that  DAA  treat-
ent  leads  to  modification  of  ADPN,  SelP  and  FetA  plasma
evels  in  HCV-infected  patients.  ADPN  improves  insulin  sen-
itivity  in  several  tissues  and  has  a  negative  correlation  with
arkers  of  IR  [3].  In  our  study,  we  observed  a  reduction  of
DPN  plasma  levels  at  the  EOT,  compared  to  baseline  values.
n  addition,  we  found  a  correlation  between  baseline  ADPN
lasma  concentrations  and  ALT  values,  a marker  of  liver  dis-
ase  and  a  positive  association  between  ADPN  plasma  levelsPlease  cite  this  article  in  press  as:  Pavone  P,  et  al.  Systemic  adipo
and  HCV/HIV  coinfected  patients  treated  with  direct  antivira
https://doi.org/10.1016/j.clinre.2018.02.004
nd  HbA1c  values  at  baseline.  These  results  could  be  con-
idered  paradoxical,  but  our  findings  are  in  accordance  to
 previous  study  performed  in  a  population  of  HCV-infected
c
3
p-infected  patients.  Plasma  levels  of  ADPN,  SelP,  FetA  and  IL-6
 significant  reduction  was  observed  for  ADPN  and  SelP.
atients  treated  with  IFN-, showing  a decrease  of  serum
DPN  levels  and  an  improvement  of  IR  in  responders  to  the
reatment  [4]. We  believe  that  the  decrease  of  ADPN  after
ntiviral  treatment  could  be  partially  explained  by  the  influ-
nce  of  hepatic  inflammation  on  ADPN  concentrations  [5].
Higher  FetA  and  SelP  plasma  levels  have  been  associated
o  IR  and  impaired  glucose  homeostasis  [6,7].  Sahar  et  al.
ave  recently  showed  that  FetA  serum  levels  are  higher  in
iabetic  and  non-diabetic  HCV  positive  patients  compared
o  healthy  population  and  that  SelP  serum  levels  are  higher
n  diabetic  HCV  positive  patients  compared  to  controls.  The
ame  study  revealed  an  association  between  FetA  and  SelP
evels  and  FG,  and  a  correlation  between  FetA  levels  and
OMA-IR  [8]. In  our  study  we  observed  a  decline  of  SelP
lasma  levels  in  HCV-positive  patients  treated  with  DAAs.
 reduction  of  FetA  was  observed  in  HCV  mono-infected
atients.  FetA  is  a  negative  acute  phase  reactant  but  it
ay  induce  low  grade  inflammation,  thus  having  pro-  and
nti-  inflammatory  properties  [7].  Our  results  in  HIV/HCV
oinfected  patients  could  be  explained  by  the  inflamma-
ory  state  related  to  HIV  infection.  IL-6  promotes  IR  and
t  has  been  related  to  the  risk  of  development  of  T2DM.
urthermore,  HCV-infected  patients  have  higher  IL-6  lev-
ls,  compared  to  the  healthy  population  [9].  Our  study  did
ot  show  a  significant  modification  of  this  cytokine  after
CV  treatment.  It  should  be  underlined  that  IL-6  levelskines,  hepatokines  and  interleukin-6  in  HCV-monoinfected
l  agents  (DAAs).  Clin  Res  Hepatol  Gastroenterol  (2018),
ould  be  influenced  by  HIV  infection  [10]  and  that  16  of
1  (52%)  patients  were  HIV-positive.  Interestingly,  an  HIV-
ositive  patient  with  decompensated  diabetes  had  a  wide
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Table  1  Adiponectin,  selenoprotein  P,  fetuin  A  and  interleukin-6  plasma  levels  at  baseline  and  end  of  HCV  DAA  treatment  according  to  the  presence  of  diabetes  and  HIV
coinfection.
Diabetes P-value Non-diabetes P-value HIV+ P-value HIV− P-value
Baseline  EOT  Baseline  EOT  Baseline  EOT  Baseline  EOT
ADPN(g/mL) 6.81  (5) 4.64  (3.98) 0.03  5.39  (10.62) 4.85  (10.65)  0.11  5.28  (11.52)  4.29  (9.11)  0.10  6.91  (4.17)  4.98  (3.5)  0.03
SelP (g/mL) 17.21(50.99)  9.88(10.23)  0.09  26.84(57.49)  11.53  (10.18) 0.005  18.12(23.98)  11.64(10.92)  0.17  24.19(81.12)  10.90(8.01)  0.0012
FetA(mg/mL) 1.78  (1.91) 1.25  (1.11) 0.28  1.77  (1.09) 1.86  (1.11) 0.35  1.63  (0.85) 1.88  (0.62) 0.44  2.49  (1.87)  1.06  (1.05)  0.02
IL-6 (pg/mL) 2.95  (5.94) 3.4  (2.82) 0.73  4.26  (3.91) 4.18  (4.65) 0.55  5.02  (5.43) 4.74  (6.90) 0.53  1.78  (2.79)  3.00  (1.78)  0.64
Results are expressed as median (Interquartile range); EOT: end of treatment; ADPN: adiponectin; SelP: selenoprotein P; FetA: fetuin A; IL-6: interleukin-6.
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eduction  of  IL-6  levels  (from  15.26  pg/mL  to  3.66  pg/mL)
nd  a  wide  reduction  of  HbA1c  (from  10.4%  to  5.9%),  whereas
elP  was  increased  at  the  EOT  and  FetA  and  ADPN  were
nchanged.  In  this  patient  it’s  plausible  that  inflammation
ad  a  key  role  in  inducing  the  HCV-related  IR.
All  together  these  results  suggest  that  altered  levels  of
dipokines/hepatokines  in  HCV  infection  can  be  restored
y  DAA  treatment,  thus  indicating  the  important  metabolic
hanges  occurring  during  the  eradication  of  this  viral  infec-
ion.
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